Surgical Innovations Group Plc
(the "Company")
Notice of Annual General Meeting
Posting of 2022 Annual Report & Accounts
Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, confirms that the Annual Report and Accounts for the year ended 31 December 2022 ("2022 Annual Report") and the Notice of the 2023 Annual General Meeting ("AGM") have now been published and can be accessed via the "Investor Centre" section of the Company's website at: www.sigroupplc.com
The 2022 Annual Report, the Notice of AGM and details voting by proxy has been posted to shareholders who have not consented to receive electronic communications.
Notice of AGM
The AGM is to be held Tuesday 27 June 2023 at 11:00 am at the Company's offices at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ and will consider the Resolutions set out in the Notice of AGM.
The Company's CEO David Marsh will also provide shareholders with a brief trading update after the formal business of the AGM concludes and there will be an opportunity for investors to ask questions. Investors can sign up to Investor Meeting Company ("IMC") for free and add to meet Surgical Innovations Group plc via:
https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor
Shareholders taking part via the IMC platform will not be able to speak or vote on the AGM resolutions. Shareholders are therefore strongly encouraged to exercise their voting rights by completing and submitting a Form of Proxy. It is highly recommended that Shareholders submit their Form of Proxy as early as possible to ensure that their votes are counted at the AGM. Shareholders are strongly encouraged to appoint the Chairman as your proxy to ensure that each Shareholder's vote will be counted in the event of restrictions on shareholders and proxies attending the AGM in person.
If you wish to attend the AGM in person and in your capacity as a shareholder wish to vote on the day, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your voting rights.
For further information please contact:
| Surgical Innovations Group plc | |||
| David Marsh, CEO | Tel: 0113 230 7597 | ||
| Charmaine Day, CFO | | ||
| | | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
| Aubrey Powell / Oliver Platts | | ||
| | | ||
| Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.